JP4225057B2 - ナテグリニドｂ型結晶の製造方法 - Google Patents

ナテグリニドｂ型結晶の製造方法 Download PDF

Info

Publication number
JP4225057B2
JP4225057B2 JP2002537707A JP2002537707A JP4225057B2 JP 4225057 B2 JP4225057 B2 JP 4225057B2 JP 2002537707 A JP2002537707 A JP 2002537707A JP 2002537707 A JP2002537707 A JP 2002537707A JP 4225057 B2 JP4225057 B2 JP 4225057B2
Authority
JP
Japan
Prior art keywords
crystals
nateglinide
type
producing
crystal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2002537707A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2002034713A1 (ja
Inventor
通人 澄川
誠 丸尾
和雄 宮崎
重宏 仁科
由紀子 松澤
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ajinomoto Co Inc
Original Assignee
Ajinomoto Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ajinomoto Co Inc filed Critical Ajinomoto Co Inc
Publication of JPWO2002034713A1 publication Critical patent/JPWO2002034713A1/ja
Application granted granted Critical
Publication of JP4225057B2 publication Critical patent/JP4225057B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C227/38—Separation; Purification; Stabilisation; Use of additives
    • C07C227/40—Separation; Purification
    • C07C227/42—Crystallisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/22—Separation; Purification; Stabilisation; Use of additives
    • C07C231/24—Separation; Purification
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2002537707A 2000-10-24 2001-10-23 ナテグリニドｂ型結晶の製造方法 Expired - Fee Related JP4225057B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2000324375 2000-10-24
JP2000324375 2000-10-24
PCT/JP2001/009293 WO2002034713A1 (en) 2000-10-24 2001-10-23 Process for producing b-form nateglinide crystal

Publications (2)

Publication Number Publication Date
JPWO2002034713A1 JPWO2002034713A1 (ja) 2004-03-04
JP4225057B2 true JP4225057B2 (ja) 2009-02-18

Family

ID=18801920

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002537707A Expired - Fee Related JP4225057B2 (ja) 2000-10-24 2001-10-23 ナテグリニドｂ型結晶の製造方法

Country Status (18)

Country Link
US (2) US20030229249A1 (OSRAM)
EP (1) EP1334964B1 (OSRAM)
JP (1) JP4225057B2 (OSRAM)
KR (1) KR100810930B1 (OSRAM)
CN (1) CN100422143C (OSRAM)
AT (1) ATE370115T1 (OSRAM)
AU (1) AU2001296001A1 (OSRAM)
BR (1) BR0114846A (OSRAM)
CA (1) CA2426745C (OSRAM)
CY (1) CY1106839T1 (OSRAM)
DE (1) DE60130014T2 (OSRAM)
DK (1) DK1334964T3 (OSRAM)
ES (1) ES2288997T3 (OSRAM)
MX (1) MXPA03003575A (OSRAM)
PT (1) PT1334964E (OSRAM)
RU (1) RU2275354C2 (OSRAM)
TW (1) TWI293290B (OSRAM)
WO (1) WO2002034713A1 (OSRAM)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2003087039A1 (ja) * 2002-04-15 2005-08-18 味の素株式会社 新規ナテグリニド結晶
US7888531B2 (en) 2002-04-15 2011-02-15 Ajinomoto Co., Inc. Nateglinide crystals

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK14922002A3 (sk) * 2000-03-17 2003-04-01 Ajinomoto Co., Inc. Farmaceutický prostriedok na prevenciu, zlepšenie a/alebo liečenie diabetickej komplikácie a použitie postprandiálnej látky na zníženie hladiny krvného cukru
PT1334962E (pt) * 2000-10-18 2007-10-09 Ajinomoto Kk ''processo de preparação de acilfenilalaninas''
BR0114729A (pt) * 2000-10-18 2003-10-14 Ajinomoto Kk Métodos para produzir cristais de nateglinida, e cristais do tipo h, cristais de nateglinida, e, cristais do tipo h de nateglinida
BR0114897A (pt) * 2000-10-24 2003-08-12 Ajinomoto Kk Preparação farmacêutica hidrofìlica contendo nateglinida, e, método para a preparação da mesma
DE60135674D1 (de) * 2000-10-24 2008-10-16 Ajinomoto Kk Nateglinid enthaltende präparate
US6861553B2 (en) 2002-07-03 2005-03-01 Teva Pharmaceuticals Industries Ltd. Process for preparing nateglinide and intermediates thereof
US7358390B2 (en) 2002-07-18 2008-04-15 Teva Pharmaceutical Industries Ltd. Polymorphic forms of nateglinide
EP1467964A1 (en) * 2002-07-18 2004-10-20 Teva Pharmaceutical Industries Limited Polymorphic forms of nateglinide
US7420084B2 (en) * 2002-07-18 2008-09-02 Teva Pharmaceutical Industries Ltd. Polymorphic forms of nateglinide
US7534913B2 (en) 2002-07-18 2009-05-19 Teva Pharmaceutica Industries Ltd. Crystalline form of nateglinide
US7148376B2 (en) 2002-07-18 2006-12-12 Teva Pharmaceutical Industries Ltd. Polymorphic forms of nateglinide
EP1535900B1 (en) * 2003-11-26 2006-12-27 A.M.S.A. ANONIMA MATERIE SINTETICHE E AFFINI S.p.A. Process for the preparation of nateglinide, preferably in b-form
KR20070009726A (ko) * 2004-05-07 2007-01-18 테바 파마슈티컬 인더스트리즈 리미티드 나테글리나이드의 다형태
US20070231393A1 (en) * 2004-05-19 2007-10-04 University Of South Carolina System and Device for Magnetic Drug Targeting with Magnetic Drug Carrier Particles
WO2005113485A2 (en) * 2004-05-20 2005-12-01 Dr. Reddy's Laboratories Ltd. Stable nateglinide form b compositions
US7425648B2 (en) 2005-01-03 2008-09-16 A.M.S.A. Anonima Materie Sintetiche E. Affini S.P.A. Process for the preparation of nateglinide, preferably in B-form
EP1891971A4 (en) * 2005-01-31 2010-02-03 Ajinomoto Kk MEDICAL COMPOSITION USING HYPERGLY CRAB MEDICAMENT TO TREAT OR TREAT GLUCOSE-INTOLERANCE, BORDERLINE DIABETES, INSULIN RESISTANCE AND HYPERINSULINEMIA
WO2007135533A1 (en) * 2006-05-23 2007-11-29 Aurobindo Pharma Limited Process for preparing nateglinide b-type crystals
KR100837843B1 (ko) * 2006-12-26 2008-06-13 씨제이제일제당 (주) 나테글리나이드 결정형, 그 제조방법, 및 그를 포함하는약제학적 조성물
KR20130087485A (ko) 2010-06-14 2013-08-06 씨아이피엘에이 엘티디. 나테글리니드의 제조 방법
WO2014037832A2 (en) 2012-09-06 2014-03-13 Mahesh Kandula Compositions and methods for the treatment of epilepsy and neurological diseases
WO2013167990A1 (en) 2012-05-07 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of depression
CA2872975A1 (en) 2012-05-07 2013-11-14 Cellixbio Private Limited Compositions and methods for the treatment of neurological disorders
US9642915B2 (en) 2012-05-07 2017-05-09 Cellix Bio Private Limited Compositions and methods for the treatment of neuromuscular disorders and neurodegenerative diseases
WO2013167991A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of metabolic disorders
US9403826B2 (en) 2012-05-08 2016-08-02 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory disorders
AU2013257708A1 (en) * 2012-05-08 2014-12-04 Cellixbio Private Limited Compositions and methods for the treatment of diabetes
US9434704B2 (en) 2012-05-08 2016-09-06 Cellix Bio Private Limited Compositions and methods for the treatment of neurological degenerative disorders
WO2013168023A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for treatment of parkinson's disease
WO2013168025A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for treatment of blood clotting disorders
US9321775B2 (en) 2012-05-10 2016-04-26 Cellix Bio Private Limited Compositions and methods for the treatment of moderate to severe pain
WO2013168005A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of restless leg syndrome and fibromyalgia
WO2013168002A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of neurological conditions
WO2013167999A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of neurologic diseases
US9273061B2 (en) 2012-05-10 2016-03-01 Cellix Bio Private Limited Compositions and methods for the treatment of chronic pain
WO2013167997A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of metabolic syndrome
WO2013168015A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of asthma and allergy
WO2013168014A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of familial amyloid polyneuropathy
WO2013168016A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of metabolic syndrome
US9573927B2 (en) 2012-05-10 2017-02-21 Cellix Bio Private Limited Compositions and methods for the treatment of severe pain
US9499526B2 (en) 2012-05-10 2016-11-22 Cellix Bio Private Limited Compositions and methods for the treatment of neurologic diseases
WO2013168012A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of respiratory disorders
US9346742B2 (en) 2012-05-10 2016-05-24 Cellix Bio Private Limited Compositions and methods for the treatment of fibromyalgia pain
US9227974B2 (en) 2012-05-23 2016-01-05 Cellex Bio Private Limited Compositions and methods for the treatment of respiratory disorders
EP2852569B1 (en) 2012-05-23 2020-10-14 Cellixbio Private Limited Compositions and methods for the treatment of multiple sclerosis
JP2015518855A (ja) 2012-05-23 2015-07-06 セリックスビオ プライヴェート リミテッド 粘膜炎の治療のための組成物および方法
US9492409B2 (en) 2012-05-23 2016-11-15 Cellix Bio Private Limited Compositions and methods for the treatment of local pain
ES2797624T3 (es) 2012-05-23 2020-12-03 Cellix Bio Private Ltd Composición para el tratamiento de la enfermedad inflamatoria intestinal
US9434729B2 (en) 2012-05-23 2016-09-06 Cellix Bio Private Limited Compositions and methods for the treatment of periodontitis and rheumatoid arthritis
US9108942B1 (en) 2014-11-05 2015-08-18 Mahesh Kandula Compositions and methods for the treatment of moderate to severe pain
WO2014020480A2 (en) 2012-08-03 2014-02-06 Mahesh Kandula Compositions and methods for the treatment migraine and neurologic diseases
WO2014037833A2 (en) 2012-09-06 2014-03-13 Mahesh Kandula Compositions and methods for the treatment inflammation and lipid disorders
CA2873029A1 (en) 2012-09-08 2014-03-13 Cellixbio Private Limited Compositions and methods for the treatment of inflammation and lipid disorders
US9333187B1 (en) 2013-05-15 2016-05-10 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory bowel disease
AU2014276346A1 (en) 2013-06-04 2015-12-24 Cellixbio Private Limited Compositions and methods for the treatment of diabetes and pre-diabetes
US9096537B1 (en) 2014-12-31 2015-08-04 Mahesh Kandula Compositions and methods for the treatment of mucositis
WO2016046835A1 (en) 2014-09-26 2016-03-31 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy and neurological disorders
WO2016051420A1 (en) 2014-09-29 2016-04-07 Cellix Bio Private Limited Compositions and methods for the treatment of multiple sclerosis
AU2014414316B2 (en) 2014-10-27 2020-04-09 Cellix Bio Private Limited Three component salts of fumaric acid monomethyl ester with piperazine or ethylene diamine for the treatment of multiple sclerosis
US9173877B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Compositions and methods for the treatment of local pain
US9175008B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Prodrugs of anti-platelet agents
US9290486B1 (en) 2014-11-05 2016-03-22 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy
US9284287B1 (en) 2014-11-05 2016-03-15 Cellix Bio Private Limited Compositions and methods for the suppression of carbonic anhydrase activity
US9321716B1 (en) 2014-11-05 2016-04-26 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic syndrome
US9150557B1 (en) 2014-11-05 2015-10-06 Cellix Bio Private Limited Compositions and methods for the treatment of hyperglycemia
US10208014B2 (en) 2014-11-05 2019-02-19 Cellix Bio Private Limited Compositions and methods for the treatment of neurological disorders
CN104402756B (zh) * 2014-11-27 2016-08-31 天方药业有限公司 一种高纯度那格列奈的制备方法
US9932294B2 (en) 2014-12-01 2018-04-03 Cellix Bio Private Limited Compositions and methods for the treatment of multiple sclerosis
US9206111B1 (en) 2014-12-17 2015-12-08 Cellix Bio Private Limited Compositions and methods for the treatment of neurological diseases
ES2905771T3 (es) 2015-01-06 2022-04-12 Cellix Bio Private Ltd Composiciones y procedimientos para el tratamiento de la inflamación y del dolor
CN109369443A (zh) * 2018-11-05 2019-02-22 扬子江药业集团江苏海慈生物药业有限公司 一种新的那格列奈h晶型的制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6354321A (ja) * 1985-03-27 1988-03-08 Ajinomoto Co Inc 血糖降下剤
AU615966B2 (en) * 1987-12-04 1991-10-17 Takeda Chemical Industries Ltd. Crystals of cephem hydrochloride
US5463116A (en) * 1991-07-30 1995-10-31 Ajinomoto Co., Inc. Crystals of N- (trans-4-isopropylcyclohexlycarbonyl)-D-phenylalanine and methods for preparing them
ES2100291T3 (es) 1991-07-30 1997-06-16 Ajinomoto Kk Cristales de n-(trans-4-isopropilciclohexilcarbonil)-d-fenilalanina y metodos para prepararlos.
EP0965339B1 (en) * 1996-11-15 2006-04-05 Ajinomoto Co., Inc. Tabletted nateglinide preparation
US6844006B1 (en) * 1999-07-09 2005-01-18 Pennfield Oil Company Process and apparatus for the preparation of chlortetracycline-containing animal feed compositions
KR20020063282A (ko) * 1999-12-28 2002-08-01 아지노모토 가부시키가이샤 경구 투여용 당뇨병 치료제
SK14922002A3 (sk) * 2000-03-17 2003-04-01 Ajinomoto Co., Inc. Farmaceutický prostriedok na prevenciu, zlepšenie a/alebo liečenie diabetickej komplikácie a použitie postprandiálnej látky na zníženie hladiny krvného cukru
BR0114729A (pt) * 2000-10-18 2003-10-14 Ajinomoto Kk Métodos para produzir cristais de nateglinida, e cristais do tipo h, cristais de nateglinida, e, cristais do tipo h de nateglinida
PT1334962E (pt) * 2000-10-18 2007-10-09 Ajinomoto Kk ''processo de preparação de acilfenilalaninas''
DE60135674D1 (de) * 2000-10-24 2008-10-16 Ajinomoto Kk Nateglinid enthaltende präparate
US7411089B2 (en) 2002-04-15 2008-08-12 Ajinomoto Co., Inc. Nateglinide crystals

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2003087039A1 (ja) * 2002-04-15 2005-08-18 味の素株式会社 新規ナテグリニド結晶
JP2010090174A (ja) * 2002-04-15 2010-04-22 Ajinomoto Co Inc 新規ナテグリニド結晶
JP4538842B2 (ja) * 2002-04-15 2010-09-08 味の素株式会社 新規ナテグリニド結晶
US7888531B2 (en) 2002-04-15 2011-02-15 Ajinomoto Co., Inc. Nateglinide crystals
US7977507B2 (en) 2002-04-15 2011-07-12 Ajinomoto Co., Inc. Nateglinide crystals

Also Published As

Publication number Publication date
PT1334964E (pt) 2007-09-20
US20070232829A1 (en) 2007-10-04
EP1334964A4 (en) 2005-09-28
BR0114846A (pt) 2004-02-25
AU2001296001A1 (en) 2002-05-06
KR100810930B1 (ko) 2008-03-10
EP1334964A1 (en) 2003-08-13
KR20030059212A (ko) 2003-07-07
DE60130014D1 (de) 2007-09-27
CY1106839T1 (el) 2012-05-23
MXPA03003575A (es) 2003-07-14
WO2002034713A1 (en) 2002-05-02
CA2426745A1 (en) 2003-04-23
JPWO2002034713A1 (ja) 2004-03-04
ATE370115T1 (de) 2007-09-15
US20030229249A1 (en) 2003-12-11
CN1483018A (zh) 2004-03-17
TWI293290B (OSRAM) 2008-02-11
DE60130014T2 (de) 2008-05-08
US7544834B2 (en) 2009-06-09
CA2426745C (en) 2009-09-15
RU2275354C2 (ru) 2006-04-27
DK1334964T3 (da) 2007-09-24
CN100422143C (zh) 2008-10-01
ES2288997T3 (es) 2008-02-01
EP1334964B1 (en) 2007-08-15

Similar Documents

Publication Publication Date Title
JP4225057B2 (ja) ナテグリニドｂ型結晶の製造方法
US6022985A (en) Process for the preparation of 4-acetoxy-2α-benzoyloxy-5β, 20-epoxy-1, 7β-10β-trihydroxy-9-oxo-tax-11-en-13α-yl(2R,3S)-3-tert-b utoxy-carbonYlamino-2-hydroxy-3-phenylpropionate trihydrate
KR920000648B1 (ko) α-L-아스파르틸-L-페닐알라닌 메틸 에스테르의 분리방법
JPS61293949A (ja) ａ−イソプロピル−ｐ−クロルフエニル酢酸の光学分割法
CN115989212A (zh) 用于合成无水乳酸的方法
JP2025041833A (ja) 結晶形ｉｉのソタグリフロジンを調製する方法
JP7595064B2 (ja) 結晶形ｉｉのソタグリフロジンを連続的に調製する方法
TW202304867A (zh) 經取代二胺基吡𠯤二羧酸之純化
US2456742A (en) Separation of isomers of amino acids
JP2004256448A (ja) ６−ヒドロキシ−２−ナフトエ酸の脱色方法
JPS6041676B2 (ja) Ｓ−２−（３−アミノプロピルアミノ）エチルジハイドロジエンホスホロチオエ−ト１水和結晶の新規製法
JP4397990B2 (ja) ３−アルキルフラバノノール誘導体の精製法
JP2957273B2 (ja) ７―クロル―キノリン―８―カルボン酸の精製方法
JP3923798B2 (ja) フマギリンの調製プロセス
JPWO2003057665A1 (ja) ベンゼンスルホンアミド誘導体結晶の製造方法、およびその中間体の新規結晶とその製造方法
CN112585122B (zh) 用于制备1,4-脱水山梨糖醇的方法
JPH0219365A (ja) ジスルフィド型サイアミン誘導体の無機酸塩の製造法
JP4694018B2 (ja) メバロラクトンメタクリル酸エステルの精製方法
CN119798107A (zh) 一种dl-泛醇的制备方法
JPS62294637A (ja) 粗イブプロフエンの精製方法
JP3191456B2 (ja) カルボン酸一無水物の製造方法
JPH1036350A (ja) ４−ヒドロキシピペリジンの精製方法
JPH0472824B2 (OSRAM)
JPS585911B2 (ja) （ ２− オキソ − ピロリジン −１ ） − アセトアミド ノ セイゾウホウホウ
JPS63139181A (ja) ２−（１０，１１−ジヒドロ−１０−オキソジベンゾ〔ｂ，ｆ〕チエピン−２−イル）プロピオン酸の結晶化方法

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20040817

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080811

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20081007

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20081104

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20081117

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20111205

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20111205

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20111205

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20121205

Year of fee payment: 4

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20121205

Year of fee payment: 4

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20131205

Year of fee payment: 5

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees